Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 73

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 73
---
025 $25,675 Stock-based compensation from:    Stock options$4,309 $5,796 $8,749 $12,525     Restricted stock units10,681 6,517 20,287 12,727     Employee stock purchase plan share options482 211 989 423         Total$15,472 $12,524 $30,025 $25,675 

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 28

Equity AwardsThe following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the six months ended June 30, 2025:Stock Options Number ofStock Options Weighted Average Exercise Price (Per Share) Outstanding at December 31, 20246,845,618 $42.95      Granted432,632 25.45      Forfeited(21,074)32.88      Expired(414,815)55.29  Outstanding at June 30, 20256,842,361 41.12 Restricted Stock Units Number ofRestrictedStock Units Weighted Average Grant Date Fair Value (Per Share)Unvested at December 31, 20242,769,728 $32.07      Granted2,355,965 26.11      Vested(722,131)37.04      Forfeited(108,615)28.77 Unvested at June 30, 20254,294,947 28.05 The weighted average fair value of stock options granted during the six months ended June 30, 2025 was $13.81 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:Black-Scholes Weighted Average AssumptionSix Months Ended June 30, 2025Expected dividend yieldNoneRisk-free interest rate4.19%Expected volatility57.8%Expected term of options5.14 yearsEmployee Stock Purchase PlanThe Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1 to June 30 and July 1 to December 31. Under the ESPP, employees